FSH is a pituitary hormone that stimulates follicle development in the ovaries and sperm production in the testes. Like LH, it's released in response to signals from the hypothalamus and regulates the reproductive axis.
FSH is one of the most reliable markers of ovarian reserve in women. Rising FSH reflects diminishing ovarian response, which is why it's used to assess fertility and detect perimenopause. Postmenopausal FSH is characteristically very high (often >30). For men, FSH primarily regulates sperm production; elevated FSH with low sperm count suggests testicular dysfunction. Interpreting FSH requires the LH context. The ratio and pattern together are more informative than either alone.
Optimal FSH: 1.5-10 mIU/mL.
Typically re-tested every 10 weeks.
It is read next to LH, estradiol or testosterone, and for women it is read next to the day of the menstrual cycle on which blood was drawn.
FSH is a glycoprotein hormone released by the anterior pituitary gland that stimulates the ovaries to recruit and mature follicles and stimulates the testes to support sperm production.
The mechanism starts higher up. The hypothalamus releases gonadotropin-releasing hormone in pulses, the pituitary responds by secreting FSH and luteinizing hormone (LH) into the bloodstream, and those two gonadotropins act on the ovaries or testes. In the ovary, FSH binds receptors on granulosa cells, driving a cohort of follicles to grow and to produce estradiol. As estradiol and the follicle-derived hormone inhibin B rise, they feed back on the pituitary and damp FSH secretion, which is why FSH is lowest when follicular activity is healthy and highest when it is not.
In the testis, FSH acts on Sertoli cells, the support cells that nurse developing sperm through their maturation and that secrete inhibin B back into circulation as a feedback signal[1]. LH does a different job, stimulating Leydig cells to make testosterone, which is why the two gonadotropins are interpreted together rather than alone.
So a single number on a lab report is really a readout of one side of a conversation. FSH tells you how loudly the pituitary is calling. Estradiol, testosterone and inhibin B tell you how well the gonads are answering.
It matters because gonadotropins often shift before sex hormones do, which makes FSH an early signal that reproductive output or pituitary signalling is changing.
The clearest example is the menopause transition. As the pool of ovarian follicles declines, inhibin B and estradiol feedback weakens and pituitary FSH secretion climbs, a pattern that unfolds over years rather than overnight and that research describes as a central feature of the neuroendocrinology of menopause[2]. Rising, erratic FSH with still-normal estradiol is a common perimenopausal picture, and it is one reason a single draw rarely settles the question.
Gonadotropins also mark the start of reproductive life. The pubertal rise in FSH and LH reflects reactivation of the hypothalamic-pituitary-gonadal axis, and systematic review work has examined factors associated with earlier pubertal timing, including body weight and environmental exposures[3]. At the other extreme, when the axis never switches on properly, gonadotropin therapy under specialist care is one of the approaches studied for inducing puberty in males with hypogonadotropic hypogonadism[4].
In adults with low testosterone or irregular cycles, FSH helps sort the problem by location. High FSH alongside low sex hormones points toward the gonad itself, while low or inappropriately normal FSH alongside low sex hormones points toward the pituitary or hypothalamus. That distinction changes what a clinician investigates next.
The downstream health relevance is mostly indirect. Sex hormone decline is associated with changes in bone density, body composition, sleep, mood and cardiometabolic markers, so a shifting gonadotropin pattern is a reason to look at the whole hormonal picture rather than a verdict on any of those outcomes.
Most adult results fall inside a typical lab reference range of 1 to 15 mIU/mL, while FitScript's optimal range is narrower.
| Marker | Typical lab reference range | FitScript optimal range |
|---|---|---|
| FSH (serum) | 1 to 15 mIU/mL | 1.5 to 10 mIU/mL |
FSH depends heavily on sex and life stage. In healthy adults, men's upper limit roughly doubled from age 45, and women's FSH rose sharply after menopause.[13]
| Sex | Age | Reference range (IU/L) |
|---|---|---|
| Men | Under 45 | 1.28 to 9.5 |
| Men | 45 and over | 2.43 to 20.2 |
| Women | Before menopause | 2.22 to 27.3 |
| Women | After menopause | 21 to 138 |
Before menopause, FSH also changes across the menstrual cycle, so the day of the cycle matters when reading a result. Your own lab's printed range is the one to read your result against.
Optimal ranges are FitScript's optimization targets, not diagnostic cut-offs. Reference ranges vary by lab, age and sex, and your own report's range is the one your clinician will use.
Three caveats matter more here than for most biomarkers. First, in menstruating women FSH changes across the cycle, peaking around mid-cycle and sitting lowest in the luteal phase, which is why fertility assessment is usually timed to the early follicular phase (commonly day 3). Second, after menopause FSH typically runs far above the premenopausal range and that elevation is expected physiology, not a problem to be corrected. Third, mIU/mL and IU/L are numerically interchangeable, but assays differ between laboratories, so trends are most meaningful when tested the same way each time.
No age-banded table is published here, because inventing age cut-offs would be worse than leaving them out. Compare your result against your own lab's range and against your own previous results.
A high FSH generally means the pituitary is pushing harder because the ovaries or testes are producing less feedback, not that the pituitary itself is overactive.
People with elevated FSH often report symptoms tied to falling sex hormones rather than to FSH itself. Women describe irregular, shortening or skipped cycles, hot flushes, disrupted sleep, vaginal dryness, mood changes and reduced libido. Men more often describe low libido, fatigue, reduced exercise recovery, smaller or softer testes and difficulty conceiving.
Common reasons a clinician considers include the perimenopausal and postmenopausal transition[2], diminished ovarian reserve at a younger age, primary ovarian insufficiency, prior chemotherapy, radiation or gonadal surgery, and in men primary testicular causes including genetic conditions, undescended testes, infection or injury. Impaired spermatogenesis associated with varicocele is another context where FSH tends to rise while inhibin B falls, a pairing that has been reviewed as a marker of Sertoli cell function[5].
The long-term angle is about what the high value reflects. Sustained low estrogen is associated with accelerated bone loss and with cardiometabolic and urogenital changes, and sustained low testosterone is associated with changes in muscle mass, bone and metabolic markers. Fertility implications also change, and interventions studied in diminished ovarian reserve, such as intraovarian platelet-rich plasma, remain experimental and clinician-gated despite early reported improvements in reproductive parameters[6].
A suboptimal or clearly elevated result is not a diagnosis. A persistently high FSH, especially with absent periods before the expected age of menopause or with infertility, is worth discussing with a clinician promptly so it can be repeated and interpreted alongside estradiol, LH and other markers.
A low FSH, particularly when sex hormones are also low, suggests the signal from the hypothalamus or pituitary is reduced rather than the gonad being exhausted.
Reported symptoms overlap confusingly with the high-FSH picture, because both end in low sex hormones. Women may notice absent or very infrequent periods, low libido and vaginal dryness. Men may notice low libido, erectile difficulty, fatigue, loss of morning erections and reduced sperm counts. Adolescents may present with delayed puberty.
Causes clinicians look for include energy availability problems such as low body weight, restrictive eating or very high training loads, significant and rapid weight loss, chronic illness or severe stress, pituitary conditions including prolactin-secreting tumours, head injury or radiation, and congenital hypogonadotropic hypogonadism. Exogenous hormones are a major and often overlooked cause: anabolic androgenic steroid use suppresses the hypothalamic-pituitary-gonadal axis, and systematic review evidence links use to suppressed gonadotropins and impaired spermatogenesis, with recovery that can take many months after stopping[7]. Prescribed testosterone produces the same suppression. Combined hormonal contraception also lowers FSH by design.
Long term, the concern is the consequence of low sex hormones rather than the low gonadotropin itself, including effects on bone density, fertility, body composition and mood. Approaches studied in this setting are all provider-decided. Gonadotropin therapy has been evaluated for pubertal induction in males with hypogonadotropic hypogonadism[4], and clomiphene citrate, which works by increasing the pituitary's own gonadotropin output, has been reviewed in men with hypogonadism[8]. FSH preparations have also been studied for selected male infertility presentations[1]. Whether any of these is appropriate is a decision a licensed provider makes after evaluating you, and no dose or schedule belongs on an education page.
More than most biomarkers, FSH is shaped by when and under what conditions you test.
Timing comes first. In menstruating women, a mid-cycle draw can look very different from a day 3 draw, so compare like with like. Menopausal status changes the expected range entirely. Hormonal contraception, testosterone, estrogen or progestin therapy, anabolic steroids and fertility medications all alter gonadotropin output[7], so your medication and supplement list should go to whoever interprets the result.
Other medications may matter indirectly. Opioids and some psychiatric medications that raise prolactin can suppress gonadotropins, and research on GLP-1 receptor agonists has examined their effects on testicular function, with findings that remain mixed and hedged rather than settled[9]. High-dose biotin supplements can interfere with some immunoassays, which is why labs often advise pausing them before testing.
Lifestyle inputs act on the axis rather than on FSH directly. Severe calorie restriction, rapid weight loss, poor sleep, heavy alcohol intake and very high training volume are all associated with reduced gonadotropin signalling. Diet quality has also drawn attention, with research examining how ultra-processed food consumption relates to male reproductive and metabolic measures[10]. In polycystic ovary syndrome, where the LH to FSH relationship is often altered, trials of vitamin D supplementation have reported effects on ovulation and pregnancy outcomes[11], and a network meta-analysis has compared several nutritional supplements in the same population[12]. Neither body of work establishes that a supplement moves FSH itself.
Finally, acute illness, recent surgery and laboratory differences between assays can all nudge a value. One unexpected result is a prompt to retest under controlled conditions, not a conclusion.
FSH is measured from a standard venous blood draw as part of a hormone panel, and it is interpreted alongside the other markers drawn at the same time.
FitScript is a labs-first membership built on 150+ biomarkers tested per year, so gonadotropins are read in context rather than in isolation: LH next to FSH, estradiol and progesterone next to both in women, and total testosterone, free testosterone and SHBG next to both in men. Atlas, FitScript's AI health advisor, turns that panel into your FitScript, the personalized output written from your own biology, including what to retest, when in the cycle to retest and which patterns are worth raising with a clinician.
Repeat testing is where the value sits. A gonadotropin result is a snapshot of a pulsatile hormone, so direction over several draws tells you more than any single number, particularly through perimenopause or while body composition, training load or medications are changing.
Where a result points toward a treatment question, the decision belongs to a licensed provider who evaluates whether any prescription therapy is appropriate for you. This article is educational and is not medical advice. Bring your results, your symptoms and your full medication list to a clinician or licensed provider before acting on anything you read here.
FSH is close to uninterpretable on its own, so pair it with the markers that describe the rest of the axis.
These are commonly drawn together on hormone lab panels, the Hormone Panel for him and the Hormone Panel for her, which is also the practical way to keep the timing consistent between draws.
FSH is the pituitary's instruction to the ovaries or testes, and the number tells you how loudly that instruction is being sent. High usually means the gonads are answering less. Low usually means the instruction itself is quiet. Neither reading is a diagnosis, both depend heavily on timing, sex, age and medications, and both are best understood as part of a panel tracked over time with a clinician involved in what happens next.
FSH stands for follicle-stimulating hormone. It is released by the anterior pituitary gland and acts on the ovaries, where it drives follicle growth and estradiol production, and on the testes, where it supports the Sertoli cells that nurse developing sperm.
A typical lab reference range for serum FSH is 1 to 15 mIU/mL, and FitScript's optimal range is 1.5 to 10 mIU/mL. Ranges vary by lab, age and sex, and postmenopausal values are expected to be far higher, so read your result against your own report's range.
FSH changes across the cycle, so it is usually drawn in the early follicular phase, commonly around day 3 counting from the first day of full flow. Testing at the same cycle point each time makes trends comparable. Your clinician may time it differently for a specific question.
Not by itself. FSH rises as ovarian follicle reserve declines, but levels fluctuate considerably through perimenopause and a single high value is not a diagnosis. Menopausal status is assessed from the pattern of results plus cycle history, age and symptoms, interpreted by a clinician.
Together they help locate where a problem sits. Both gonadotropins high with low sex hormones points toward the ovary or testis; both low or inappropriately normal with low sex hormones points toward the pituitary or hypothalamus. Their relative balance is also assessed in polycystic ovary syndrome.
It is commonly included when low testosterone symptoms or fertility concerns are being investigated, because FSH reflects Sertoli cell and sperm-production signalling rather than testosterone output. It is most informative alongside LH, total and free testosterone and SHBG. A clinician decides what testing is appropriate.
Yes. Combined hormonal contraception lowers FSH by design, and prescribed testosterone or anabolic steroid use suppresses the whole hypothalamic-pituitary-gonadal axis, including FSH. Always tell whoever interprets your result about every hormone, medication and supplement you take, including high-dose biotin.
It gives a partial signal, not a prediction. Early follicular FSH is one marker of ovarian reserve and is usually read with estradiol, AMH and antral follicle count, while in men it is read with semen analysis. Fertility assessment belongs with a clinician who sees the full picture.
Sometimes. When a low result reflects energy deficiency, rapid weight loss, heavy training or exogenous hormone use, the axis may recover once the cause is addressed, although recovery after androgen use can take many months. Elevation from declining ovarian reserve generally does not reverse.